Expert Interview
Discussing the standard of care and potential of AstraZeneca’s Farxiga (dapagliflozin), an oral once-daily SGLT2 inhibitor, which recently received FDA approval of label expansion to treat heart failure in a broader range of patients.
Ticker(s): AZNInstitution: Penn Medicine
- Echo Lab Director, Vascular Lab Director, and Clinical Assistant Professor of Medicine at Penn Medicine Valley Forge
- Areas of expertise include Aortic Disorders, Atherosclerosis, Paroxysmal Supraventricular Tachycardia, Hypertension
- Manages approximately 500 patients with heart failure, and prescribes Farxiga for about 50 patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
